Founders, investors sound off on Houston's VC scene, energy innovation potential, and more

EAVESDROPPING in Houston

Hit the highlights of Venture Houston 2023 with these overheard moments from the event. Photo courtesy of HX Venture Fund

Last week, nearly 1,000 people convened in Houston to discuss venture capital activity, startups, and decarbonization, and the Houston factor among it all.

On September 7, Venture Houston hosted several keynote addresses and panels throughout the day's programming, and investors from across the country discussed with Houston-based startup and corporate leaders on topics from seed funding to cultivating an ecosystem.

The annual event, presented by HX Venture Fund, a fund of funds that deploys capital into VC funds with an interest in Houston, had one significant through line throughout the day, and it was Houston's role within innovation and the energy transition.

Whether you missed the event or were there to soak in every second, here's a roundup of key statements on this topic from the panelists.

“We mapped out Texas as a high priority because we knew you can’t do energy without Texas. You can’t do energy without Houston."

— Carmichael Roberts, investment committee co-lead for Breakthrough Ventures. "The opportunity that Houston has to be the unambiguous leader is because everywhere else can do energy transition, but they still can’t do what Houston does,” he continues.

“There’s no better place in the world than Houston to build and scale a climate tech startup.”

— Tim Latimer, CEO and co-founder of Fervo Energy. “But I don’t know if I’m ready to make the claim that we’re the best place to start a business,” he adds.

“Houston needs that first, higher-profile investor who’s Houston-based, Houston-first, and wants to put as much capital as possible into energy transition and climate tech companies.”

— Craig Wilson, managing director of NYU’s Tandon Future Labs. “Houston is blessed with an incredible amount of CVC and late stage capital," he continues. "What it really could use is early stage capital.”

“There are a couple aspects you need for an ecosystem, and Houston has been putting a lot of those in place, but it’s not perfect yet, and there’s still work that this ecosystem needs to do."

— Trevor Best, CEO and co-founder of Syzygy Plasmonics. Startups need talent, facilities, capital, and customers. “Here in Houston, for energy transition technologies, I don’t know if there’s an ecosystem that can check the box (for customers) stronger than Houston," he adds, explaining that talent is here too. Where Houston needs improvement, according to Best, is in facilities, which is seeing some progress, and capital development.

“I think Houston is actually the perfect place for becoming the energy transition capital. If you ask me, I think we already are.” 

— Andrea Course, venture principal of Shell Ventures. “It really just takes people doing what we’re doing now to make it even greater," she adds.

“We have to figure out ways for how big energy companies work with new technology providers in partnership and not say it’s a David versus Goliath thing.”

— Gaurab Chakrabarti, co-founder and CEO of Solugen. “That’s a philosophical misalignment,” he continues. “Instead of saying it’s an absolute problem, accept that it’s a transition.”

From Your Site Articles
This week's roundup of Houston innovators includes Tim Neal of AmPd Labs, Sandy Guitar of HX Venture Fund, and Sahir Ali of Modi Ventures. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from venture capital to manufacturing — recently making headlines in Houston innovation.

Tim Neal, CEO of AmPd Labs

Tim Neal is the new CEO of AmPd Labs, a unique additive manufacturing startup in Houston. Photo via LinkedIn

Houston entrepreneur Tim Neal joined next-generation additive manufacturing company AmPd Labs as CEO of the company. He tells InnovationMap that he'd always been interested in the additive manufacturing sector, and sees a lot of potential for AmPd Labs in the industrial world in Houston — now more than ever.

“Within additive manufacturing, a lot of people focus on the medical and the aerospace sectors, but the industrial sector has been largely overlooked. Being in Houston, that really resonates,” Neal says. “The technology is now at a place that it can be at this production scale.” Read more.

Sandy Guitar, general partner of HX Venture Fund

Sandy Guitar shares some lessons learned from the fallout of Silicon Valley Bank. Photo via HXVF

In its third year, Venture Houston — taking place on Rice University's campus on September 7 — has a theme of "decarbonization in a digital world," but that's not the only thing different this year. The one-day conference has added on a unique event on September 6 to help engage around 50 investors with over 100 Houston startups.

The new activation is called Capital Connect, and HX Venture Fund will matchmake investors and startups for one-on-one meetings meant to spur collisions and collaboration.

"It's not a pitch competition — it doesn't have the stress of that," Sandy Guitar, general partner of HX Venture Fund, tells InnovationMap. "It's really just a way of connecting with a longer term horizon. We didn't want to limit it just to those who are currently raising, but actually include people who maybe just raised six months ago or are not going to raise for 12 more months, but might still want to be in the room." Read more.

Sahir Ali, founder and general partner of Modi Ventures

Sahir Ali is the founder and general partner of Modi Ventures. Photo courtesy of Modi Ventures

It might be cool to arrive fashionably late to a party, but Houston investor Sahir Ali likes to be early when it comes to new technologies.

"What has been a part of my success and has driven a lot of my profesional, scientific, and financial growth has been being ahead of the curve a little bit in technologies. That is really the basis of the fund," Ali, founder and general partner of Modi Ventures, says on the Houston Innovators Podcast.

"Hardware and software have come to a point where now artificial intelligence is ready to go, and I think the biggest benefactor of that is going to be health care and the health and medicine space — and that space is not easy for investors to just jump in right away," he continues. Read more.

Venture Houston is back next month. Here's what you need to know about this year's changes. Photo via LinkedIn

Houston VC conference returns to prioritize decarbonization, curated connections

can't miss event

In two weeks, hundreds of investors, corporate partners, and startups will convene to tackle topics of decarbonization, innovation, and investment. The annual event is also prioritizing something this year — connections.

In its third year, Venture Houston — taking place on Rice University's campus on September 7 — has a theme of "decarbonization in a digital world," but that's not the only thing different this year. The one-day conference has added on a unique event on September 6 to help engage around 50 investors with over 100 Houston startups.

The new activation is called Capital Connect, and HX Venture Fund will matchmake investors and startups for one-on-one meetings meant to spur collisions and collaboration.

"It's not a pitch competition — it doesn't have the stress of that," Sandy Guitar, general partner of HX Venture Fund, tells InnovationMap. "It's really just a way of connecting with a longer term horizon. We didn't want to limit it just to those who are currently raising, but actually include people who maybe just raised six months ago or are not going to raise for 12 more months, but might still want to be in the room."

The official day of the conference will also feature networking opportunities, including a breakfast hosted by DivInc, as well as networking breaks throughout the day.

"Based on feedback we received last year, networking was one of the things that was most celebrated about Venture Houston 2022," Guitar says. "All that space and time — the opportunity to allow people just to connect with one another. So, we're making sure that's a key part of this year as well."

Last year's keynote panel featured Gwyneth Paltrow, who shared her own founder's journey on the Venture Houston stage. This year's keynote address will be with Carmichael Roberts, investment committee co-lead of Breakthrough Energy Ventures, which was founded by Bill Gates to support climate change innovation.

While the topic of decarbonization might sound narrow, Guitar emphasizes that this event will not just be for the energy industry. Business everywhere — but especially in Houston — has an increased calling to decarbonization.

"I do think it's important to see the decarbonization not as a hard tech event, but as everything that touches carbon, which is basically everything in our planet in just the coal previously," she says. "Everything we make and use touches the climate."

Guitar adds that HXVF expects a crowd of around 1,000 people to attend the event this year, which would make it one of the largest VC-focused events ever to be held in the region. InnovationMap and EnergyCapital are media partners for the event.

This week's roundup of Houston innovators includes Gaurab Chakrabarti of Solugen, Sandy Guitar of HX Venture Fund, and Cameron Owen of rBIO. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from synthetic biology to venture capital — recently making headlines in Houston innovation.

Gaurab Chakrabarti, the CEO and co-founder of Solugen

Gaurab Chakrabarti shared his entrepreneurial journey on the SXSW stage this year. Photo courtesy of the Greater Houston Partnership

Houston doesn't have too many unicorns — startups valued at $1 billion or more — in its innovation ecosystem, but Solugen, a sustainable chemicals company, is among the elite group. Gaurab Chakrabarti, the CEO and co-founder of the company, joined Houston House by the Greater Houston Partnership, to share his story on the SXSW stage.

“You do make your own luck, but you have to be putting in the work to do it," Chakrabarti says, adding that it's not an easy thing to accomplish. “There are things you can be doing to increase your luck surface area."

He shared several lessons he learned on his founder journey in the discussion. Read more. 

Sandy Guitar, managing director of HX Venture Fund

Sandy Guitar shares some lessons learned from the fallout of Silicon Valley Bank. Photo via HXVF

Following the failure of Silicon Valley Bank, there's one thing Sandy Guitar can say has changed for Houston innovators: Bank diversification is going to be a must.

“We didn't think we needed one last week, but this week we know we need a resilience plan," she says, explaining that bank diversification is going to be added to "the operational due diligence playbook." Read more.

Cameron Owen, co-founder and CEO of rBIO

San Diego-based rBIO moved to Houston to take advantage of the growing ecosystem of biomanufacturing and synthetic biology. Photo courtesy of rBIO

Founded in San Diego, rBIO recently relocated to Houston and has big plans for settling in the city, says Cameron Owen, the company's co-founder and CEO.

“Companies from California like us and the coastal areas were converging here in Houston and creating this new type of bioeconomy,” he tells InnovationMap.

He shares that Houston wasn't originally on his radar, until it was. A visit turned into a relocation, and it's just the beginning for the biotech startup that's focused on using synthetic biology for pharmaceuticals. Read more.

Last weekend was a tumultuous one for founders and funders in Houston and beyond. Here's what lessons were learned. Photo via Getty Images

Following Silicon Valley Bank collapse, banking diversification is key for Houston founders

SVB shake up

Last week, Houston founder Emily Cisek was in between meetings with customers and potential investors in Austin while she was in town for SXSW. She was aware of the uncertainty with Silicon Valley Bank, but the significance of what was happening didn't hit her until she got into an Uber on Friday only to find that her payment was declined.

“Being positive in nature as I am, and with the close relationship that I have with SVB and how they’ve truly been a partner, I just thought, ‘OK, they’re going to figure it out. I trust in them,'” Cisek says.

Like many startup founders, Cisek, the CEO of The Postage, a Houston-based tech platform that enables digital legacy planning tools, is a Silicon Valley Bank customer. Within a few hours, she rallied her board and team to figure out what they needed to do, including making plans for payroll. She juggled all this while attending her meetings and SXSW events — which, coincidentally, were mostly related to the banking and fintech industries.

Sandy Guitar had a similar weekend of uncertainty. As managing director of HX Venture Fund, a fund of funds that deploys capital to venture capital firms around the country and connects them to the Houston innovation ecosystem, her first concern was to evaluate the effect on HXVF's network. In this case, that meant the fund's limited partners, its portfolio of venture firms, and, by extension, the firms' portfolios of startup companies.

“We ultimately had no financial impact on venture fund 1 or 2 or on any of our portfolio funds or our underlying companies,” Guitar tells InnovationMap. “But that is thanks to the Sunday night decision to ensure all deposits.”

On Sunday afternoon, the Federal Deposit Insurance Corp. took control of SVB and announced that all accounts would be fully insured, not just up to the $250,000 cap. Customers like Cisek had access to their accounts on Monday.

“In the shorter term, the great news is SVB entity seems to be largely up and functioning in a business as usual manner,” Guitar says. “And they have a new leadership team, but their existing systems and predominantly the existing employee base is working well. And what we're hearing is that business as usual is taking place.”

Time to diversify

In light of the ordeal, Guitar says Houston founders and funders can take away a key lesson learned: The importance of bank diversification.

“We didn't think we needed one last week, but this week we know we need a resilience plan," she says, explaining that bank diversification is going to be added to "the operational due diligence playbook."

"We need to encourage our portfolio funds to maintain at least two banking relationships and make sure they're diversifying their cash exposure," she says.

A valued entity

Guitar says SVB is an integral part of the innovation ecosystem, and she believes it will continue on to be, but factoring in the importance of resilience and diversification.

"Silicon Valley Bank and the function that they have historically provided is is vital to the venture ecosystem," she says. "We do have confidence that either SVB, as it is currently structured or in a new structure to come, will continue to provide this kind of function for founders."

Cisek, who hasn't moved any of her company's money out of SVB, has similar sentiments about the importance of the bank for startups. She says she's grateful to the local Houston and Austin teams for opening doors, making connections, and taking chances for her that other banks don't do.

"I credit them to really being partners with startups — down to the relationships they connect you with," she says. "Some of my best friends who are founders came from introductions from SVB. I've seen them take risks that other banks won't do."

With plans to raise funding this yea, Cisek says she's already started her research on how to diversify her banking situation and is looking into programs that will help her do that.

Staying aware

Guitar's last piece of advice is to remain confident in the system, while staying tuned into what's happening across the spectrum.

“This situation that is central to the venture ecosystem is an evolving one," she says. "We all need to keep calm and confident in business as usual in the short term while keeping an eye to the medium term so that we know what happens next with this important bank and with other associated banks in the in our industry."

Here's your latest roundup of innovation news you may have missed. Photo via Getty Images

Houston unicorn raises $200M series D, startup snags national award, and more innovation news

Short stories

It's been a busy month so far with plenty of Houston startup news, major ecosystem events, and more — and there might be some headlines you may have missed.

In this roundup of short stories within Houston startups and tech, Solugen raises another mega round of funding, CorInnova snags a prestigious award, applications are open for two programs, and more.

Houston unicorn chemicals company raises $200M series D

Solugen closed its Series d funding round at $200 million. Photo via Getty Images

Houston-based Solugen has announced its latest round of investment to the tune of $200 million. The company, which reached unicorn status after its $357 million series C round last year, uses its patented Bioforge processes to produce "green" chemicals from bio-based feedstocks.

"Solugen is reimagining the chemistry of everyday life with enzymes found in nature. We make chemicals better, faster, cheaper, and without fossil fuels from right here in Houston, Texas. Whether you care about the climate, local competitiveness, or just plain old profits, we have good news: it's working," the company states in its news release.

"Our first Bioforge has been operating for a year and Solugen is running a nearly nine figure business with high margins selling commodity and specialty chemicals," the statement continues. "We have established ourselves with top tier customers for our existing solutions and fortune 100 technology partners to build a robust pipeline of future molecules that will help us achieve our goal of 10 mil tons of CO2 removed from the atmosphere."

According to the company, this latest raise has increased Solugen's valuation to over $2 billion. The round was led by investors Kennivik, Lowercarbon Capital, and Refactor Capital.

Houston health tech company wins funding from national organization

CorInnova has won a prestigious award. Photo via corinnova.com

Houston-based CorInnova was named one of five awardees from the National Capital Consortium for Pediatric Device Innovation's “Make Your Medical Device Pitch for Kids!” competition. Each honoree received a share of $150,000 in grant funding from the U.S. Food and Drug Administration. The awards ranged from $20,000 to $50,000 to support the advancement of pediatric medical devices.

CorInnova has designed a minimally invasive biventricular non-blood contacting cardiac assist device to treat heart failure.

The 2022 competition was moderated by California-based MedTech Innovator. The other four pediatric device innovation awardees included:

  • Innovation Lab, from La Palma, California, created a mechanical elbow brace stabilizes tremors for pediatric ataxic cerebral palsy to improve the performance of Activities of Daily Living.
  • Prapela, based in Biddeford, Maine, created the first innovation to improve the treatment of apnea of prematurity in over twenty years.
  • Tympanogen, from Richmond, Virginia, replaces surgical eardrum repair with a nonsurgical clinic procedure
  • Xpan, based in Concord, Ontario, has created a universal trocar enables safest and most dynamic access and effortless upsizing in conventional/mini/robotic procedures.

"We are delighted to recognize these five innovations with critical NCC-PDI funding that will support their journey to commercialization. Improving pediatric healthcare is not possible without forward-thinking companies that seek to address the most dire unmet needs in children’s health,” says Kolaleh Eskandanian, vice president and chief innovation officer at Children’s National Hospital and principal investigator of NCC-PDI, in a news release. "We know all too well how challenging it is to bring pediatric medical devices to market, which is why we have created this rich ecosystem to identify promising medical device technologies and incentivize investment. We congratulate this year’s winning innovators and applaud their efforts to help bridge these important care gaps that are impacting children.”

Houston real estate tech scores funding from Amazon entity

DOSS is a real estate tech company. Photo via Getty Images

Houston-based DOSS, which was chosen this summer for the inaugural Black Founders Build with Alexa cohort, has received funding from the Amazon Alexa Fund. The startups in the program were selected based on their ability to innovate with Alexa and build the next generation of voice, artificial intelligence, and ambient experiences technology.

DOSS is a digital brokerage that uses tech to make homeownership more affordable, and the company has developed a technology where customers are able to ask for real-estate advice and tips, search for home listings, get neighborhood information, and recent sales data, according to a news release from the company. They will also eventually be able to request to be connected with home service providers that serve their respective area.

CEO Bobby Bryant and COO Chris Norton founded DOSS in 2016. Last year, the company participated in the Google for Startups Black Founders program, receiving $100,000 from the fund.

TMC Innovation's Biodesign program applications open

Applications are open through the end of the year. Photo via tmc.edu

Applications are now open for the 2023 TMCi Biodesign program at the Texas Medical Center's Innovation Factory. TMC is looking for candidates with relevant backgrounds for starting a digital health or medical device company, such as: engineering, medicine, hospital administration, R&D (prototyping), software development, finance, legal, regulatory, reimbursement, or technical. Candidates must have at least 1 to 2 years of industry work experience or have prior startup history. It is preferred that applicants have earned an advanced degree.

The position is an in-person, full-time requirement that will begin August 2023 and will span nine months with an opportunity to extend for up to two months.

Applications close on December 31. Candidates will undergo a series of interviews in January and then will be extended offers in the spring.

HX Venture Fund calls for startups to meet visiting VC

Calling all Houston tech startups. Image via Screenshot

HX Venture Fund, a fund-of-funds that encourages and enables non Houston-based VCs to tap into the local innovation ecosystem, is hosting Creighton Hicks, partner at Austin-based LiveOak Venture Partners, later this month.

The organization is looking for Houston startups that are building a tech or tech-enabled services company raising a seed to series B round now or in the next six months. Startups have until November 18 to submit their interest via an online form.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings